🎁 💸 Warren Buffett's Top Picks Are Up +49.1%. Copy Them to Your Watchlist – For FreeCopy Portfolio

UPDATE 3-Australia hails vaccine deal as virus surge abates

Published 19/08/2020, 10:34 am
CSL
-
AZN
-

(Adds Australia's total new cases in paragraph 16)

By Renju Jose and Sonali Paul

SYDNEY/MELBOURNE, Aug 19 (Reuters) - A fresh outbreak of infections in Australia's coronavirus hot zone of Victoria eased further on Wednesday, while the country agreed a deal to secure a potential COVID-19 vaccine that it plans to roll out cost-free to citizens.

Australia has signed a deal with British drugmaker AstraZeneca AZN.L to produce and distribute enough doses of a potential coronavirus vaccine for its population of 25 million, Prime Minister Scott Morrison said late on Tuesday. we be in a position for the trials to be successful, we would hope that this would be made available early next year. If it can be done sooner than that, great," Morrison said on Wednesday.

All Australians will be offered doses but a medical panel will determine the priority list of vaccine recipients.

"Naturally you would be focusing on the most vulnerable, the elderly, health workers, people with disabilities in terms of the speed of roll out," Health Minister Greg Hunt told Sky News.

Health authorities would also have to take into account where the highest risk of transmission is and how the vaccine works in different age groups when deciding who should get it first, Victoria's chief health officer Brett Sutton said.

"If it does work and it's 80 to 90% effective, then absolutely it will be a game changer," Sutton said, although he cautioned that broad testing was still at a preliminary stage. "So we shouldn't hang our hats on a single vaccine."

AstraZeneca last month said good data was coming in so far on its vaccine for COVID-19, already in large-scale human trials and widely seen as the front-runner in the race for a shot against the novel coronavirus. vaccine, called AZD1222, was developed by Britain's University of Oxford and licensed to AstraZeneca.

Morrison said Australia was also looking for other vaccine deals, including with the University of Queensland and its partner, Australian firm CSL Ltd CSL.AX .

CSL estimates first doses of the University of Queensland vaccine will be available for emergency use by the middle of 2021, Chief Executive Paul Perrault told reporters on Wednesday.

CSL said its first priority would be manufacturing the UQ vaccine, but it was also in talks to help AstraZeneca manufacture its vaccine.

Morrison said Australia is also talking to its Pacific neighbours, including Indonesia, Papua New Guinea and Fiji, about supplying vaccine.

A flare-up in infections in Australia's second most populous state of Victoria forced authorities two weeks ago to impose a nightly curfew and shut large parts of the state's economy.

The state has seen a slowdown in new cases in recent days, allaying fears of a nationwide second wave.

There were 12 deaths and 216 new cases in the past 24 hours, down from more than 700 infections two weeks ago. There were just 12 new cases in three other states.

Despite the surge in the past month, Australia has avoided the high casualties of other nations with just under 24,000 infections and 450 deaths from the virus.

<^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ FACTBOX-AstraZeneca's potential coronavirus vaccine

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.